Two Cases of HER2-negative Recurrent Breast Cancer Treated with Olaparib as a Second and Third Line of Therapy with Good Responses

DOI Web Site Web Site 7 References
  • KIN Takanori
    Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
  • UENO Ayako
    Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
  • TAKAMATSU Yuri
    Department of Breast Surgery, Sanwa Hospital
  • ITO Mitsuya
    Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
  • KAWASAKI Kensuke
    Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
  • OHTANI Shoichiro
    Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital

Bibliographic Information

Other Title
  • 二次・三次治療でオラパリブの著効をみたHER2陰性再発乳癌の2例
  • 症例 二次・三次治療でオラパリブの著効をみたHER2陰性再発乳癌の2例
  • ショウレイ ニジ ・ サンジ チリョウ デ オラパリブ ノ チョコウ オ ミタ HER2 インセイ サイハツ ニュウガン ノ 2レイ

Search this article

Abstract

<p>Though olaparib was approved for use in Japan in 2018, there have been few reported cases due to few eligibility for its use. Here, we report two cases of breast cancer that showed good responses to olaparib. The first case was a 44-year-old woman with right breast cancer (T2N2aM0 stage IIIA, luminal type) who relapsed 2 years after breast surgery with lung metastasis. Hormone and oral anticancer therapies were administered. A BRCA2 mutation was detected, and olaparib was administered as a third-line treatment. A partial response was maintained for 8 months. The second case was a 69-year-old woman with bilateral breast cancer (left is T2N0M0 stage IIA, luminal type ; right details unknown) who relapsed 13 years and 4 months after left breast surgery with abdominal para-aortic lymph nodes (triple-negative on biopsy), right ovary, and peritoneal metastasis. Oral anticancer drugs were administered. A BRCA1 mutation was detected, and olaparib was administered as a second-line treatment. Partial response was maintained for 4 months. In both cases, olaparib was administered as an early line of therapy (as in the OlympiAD trial) and showed good response.</p>

Journal

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top